Boost For Blood Cancer Sufferers
20 May 2011, 10:25
Southampton General Hospital has been named as a centre in a unique new clinical trial network with access to millions of pounds worth of life-saving drugs for blood cancer patients.
Southampton will be one of just thirteen centres in the national network, set up by the charity Leukaemia & Lymphoma Research in response to poor survival rates for many types of leukaemia, lymphoma and myeloma.
The network is central to Leukaemia & Lymphoma Research’s vision to deliver ‘Tomorrow’s Treatments Today’ for blood cancer patients. Southampton General Hospital will be allocated a research nurse to help recruit patients who are not responding to current treatment. They will also deal with the time-consuming paper work associated with setting up clinical trials for promising new drugs.
Blood cancers are the most common cause of cancer deaths in the under 35s, with new figures released by the charity showing that over 12,000 people are dying of blood cancers each year. With some exceptions, survival rates have improved very little for most forms of blood cancer in the last decade.
Leukaemia & Lymphoma Research Clinical Trials Coordinator, Dr Andrew Davies, Senior Lecturer and Consultant Oncologist at Southampton General Hospital, said: “Being part of this clinical trials network will increase the access of blood cancer patients in Southampton to new drugs and treatments that offer hope to those who do not respond to current treatments.”
There are so many different blood cancers that it has often been seen as uneconomical to develop drugs for many types. When new drugs are available, often clinical trials are not set up because of the difficulties of recruiting enough patients at a single hospital to make them workable.
Because trials will be linked up to other hospitals in the new national network, individual patients with even very rare blood cancers will now be able to be treated with new drugs at Southampton General Hospital, rather than having to travel to get on a clinical trial suited to them. The first trials are expected to be entered into the network by the end of the year.
Cathy Gilman, Chief Executive of Leukaemia & Lymphoma Research, said:
“Thanks to 50 years of investment in research by Leukaemia & Lymphoma Research, a lot is known about the basic biology of blood cancers. We are now in a position to translate this knowledge from lab bench to bedside. Our investment will set in place a unique infrastructure to co-ordinate world class trials and deliver ‘Tomorrow’s Treatments Today’ – giving more blood cancer patients in Southampton a future.”